Evidence map›Paper›PMID 40952259›Full record

ArticleJournal of virology2025

Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2.

Rubaiyea Farrukee, Francesca Mordant, Charley Mackenzie-Kludas, Dejan Mesner, Masahiro Yamomoto, Clare Jolly, Andrew G Brooks, Kanta Subbarao, Sarah L Londrigan, Patrick C Reading

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rubaiyea FarrukeeDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-9023-246X
Francesca MordantDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Charley Mackenzie-KludasDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Dejan MesnerDivision of Infection and Immunity, University College London, London, United Kingdom.
Masahiro YamomotoDepartment of Immunoparasitology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
Clare JollyDivision of Infection and Immunity, University College London, London, United Kingdom.ORCID 0000-0002-4603-2281
Andrew G BrooksDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-1713-3056
Sarah L LondriganDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-0989-4971
Patrick C ReadingDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-8860-5308

Funding

Australian Government Department of Health N/AGlobal Virus Network Postdoctoral FellowshipUniversity of Melbourne Early Career Research GrantWellcome TrustWellcome Trust 223065
6 · The paper itself

Abstract

Severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are associated with significant morbidity and mortality worldwide. Identification and characterization of intracellular proteins with antiviral activity (known as restriction factors) is a key first step towards the future development of novel host-directed antiviral therapies. In this study, we investigated the antiviral activity of 14 different interferon-stimulated gene (ISG) proteins against SARS-CoV-2. Overexpression of human guanylate binding protein (GBP) 1 resulted in potent inhibition of the ancestral SARS-CoV-2 strain, as well as against Alpha, Beta, Delta, Omicron BA.1, and Omicron BA.2 variants of concern (VOCs). Moreover, knockdown or knockout of endogenous human GBP1 resulted in enhanced titers of SARS-CoV-2. While hGBP1 can restrict some viruses via actin remodeling, our data indicate that this is not the mechanism here. Moreover, we show that unlike GBP2 and GBP5, which impair spike protein processing, GBP1 did not reduce infectivity of spike-pseudotyped viruses following titration on Caco-2 cells. Multiple human GBPs have been reported to inhibit SARS-CoV-2

Indexed as

COVID-19GTP-Binding ProteinsSARS-CoV-2Virus ReplicationAnimalsChlorocebus aethiopsHEK293 CellsHumansMiceMice, KnockoutSpike Glycoprotein, CoronavirusVero CellsGBP1 protein, humanGTP-Binding ProteinsSpike Glycoprotein, CoronavirusGBP1innate immunityrestriction factorsSARS-CoV-2

Identifiers

PMID40952259
PMCPMC12548390

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.